Denosumab, an anti-RANKL antibody, blocks RANKL-RANK binding, thereby inhibiting osteoclast differentiation and preventing RA-associated bone erosion, although it does not prevent inflammation10. The gene discussed is TNFRSF11A; the disease is rheumatoid arthritis.